Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05022849 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
A Phase 1 study of Prostatic Neoplasms, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 8
- Study locations
NCT05022849 is a Phase 1 study of Prostatic Neoplasms that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 15 participants, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (97% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT05022849, a Phase 1 study of Prostatic Neoplasms, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).
Conditions Studied
Interventions
- DRUG JNJ-75229414
- DRUG Bridging Therapy
Study Locations (8)
New York
- Icahn School of Medicine at Mount Sinai - New York
- Columbia University Medical Center - New York
California
- City of Hope Cancer Center - Duarte
Kentucky
- Norton Cancer Institute - Louisville
Minnesota
- University Of Minnesota - Minneapolis
North Carolina
- Levine Cancer Institute - Charlotte
Pennsylvania
- University of Pennsylvania - Philadelphia
Utah
- University of Utah Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-09-28 |
| Est. Completion | 2037-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05022849
The ClinicalTrials.gov registry entry for NCT05022849 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (97% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which JNJ-75229414 is the first listed.
NCT05022849 reports 8 study locations spanning 7 distinct geographic areas - top geographies include New York, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT05022849 about?
NCT05022849 is a clinical study titled "A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants". The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).
What is the current status of trial NCT05022849?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-09-28. Estimated completion is 2037-10-30.
What conditions does trial NCT05022849 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT05022849?
The interventions under investigation include: JNJ-75229414 (DRUG), Bridging Therapy (DRUG).
Who is sponsoring clinical trial NCT05022849?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05022849 being conducted?
This trial has 8 study locations across California, Kentucky, Minnesota, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
RECRUITING · Phase 1
-
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
RECRUITING · Phase 1
-
A Study of DM002 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.